Top Markets
Coin of the day
TWi Biotechnology, Inc. TWi Biotechnology, Inc.

TWi Biotechnology, Inc.

6610
Peringkat dalam Saham #17310
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Harga Saham
$1.21
Kapitalisasi Pasar
$248.41M
Perubahan (1 hari)
4.11%
Perubahan (1 tahun)
79.12%
Negara
TW
Perdagangan TWi Biotechnology, Inc. (6610)

Kategori

Rasio P/S untuk TWi Biotechnology, Inc. (6610)
Rasio P/S per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari TWi Biotechnology, Inc., rasio P/S saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/S perusahaan adalah 0.
Riwayat rasio P/S untuk TWi Biotechnology, Inc. dari 2026 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH